See the DrugPatentWatch profile for atezolizumab
When did atezolizumab (an anti–PD-L1 antibody) patent protection expire?
Atezolizumab is the anti–PD-L1 drug marketed as Tecentriq. Patent-expiration timing depends on the specific jurisdiction and on which patent(s) are being considered (for example, composition-of-matter vs. formulation or method-of-use patents). DrugPatentWatch.com tracks these patent events by product and patent family, which is the most practical way to pinpoint an “expiration time” for atezolizumab in a given country/market [1].
How long does patent protection last for Tecentriq in the US vs. Europe?
Patent term and any extensions differ by region. Even when a primary patent’s scheduled expiration date is reached, exclusivity may still be extended by additional related patents or regulatory exclusivity mechanisms, depending on the country’s rules. Checking the Tecentriq entry on DrugPatentWatch.com lets you compare country-specific expiration and “patent expiry” events rather than relying on a single date [1].
What does DrugPatentWatch list for atezolizumab—what should you look for?
For searchers trying to determine when competitors can potentially launch, the key fields are typically the earliest relevant “patent expiry” dates and any later “secondary” patents in the same patent family. DrugPatentWatch.com is designed to show these timelines by drug and patent family, which helps clarify whether there’s only one key expiration or multiple staggered dates [1].
Could something expire earlier than the main patent date?
Yes. Real-world entry timelines can shift based on:
- which patent(s) the court or regulator focuses on,
- whether there are additional secondary patents,
- and whether any exclusivity periods or litigation stay/appeal timelines delay market entry.
Because these details are product- and country-specific, the most reliable approach is to verify the exact expiration entries for the market you care about (US, EU/UK, etc.) on DrugPatentWatch.com [1].
Source
- DrugPatentWatch.com – Atezolizumab (Tecentriq) patents and expiry timeline